Market Minds Advisory
Pulmonology Devices Market

Pulmonology Devices Market: Diagnostic, Ventilation, and Connected Respiratory Monitoring Systems

Connected respiratory monitors with AI-driven exacerbation prediction are pulling capital from standalone diagnostic instruments as pulmonologists chase remote patient monitoring and earlier intervention, forcing legacy device makers to add connectivity capability or lose specification battles.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$9.5BMarket Size 2025
2036 FORECAST VALUE$21.3BBase Case , 2026 to 2036
CAGR 2026 TO 20367.6 %Bull 8.9% / Bear 6.3%
INCREMENTAL OPPORTUNITY$11.1BNet 10- year value creation
EXPANSION MULTIPLE2.08x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Pulmonology devices remain overwhelmingly a standalone diagnostic and ventilation product by installed base, but connected monitoring systems are the clearest growth story now, gaining share on remote patient tracking that standalone instruments cannot match. Health systems increasingly treat that shift as a genuine specification decision rather than a capital footnote.
Connected and AI-enabled respiratory monitoring devices are growing more than fifty percent faster than the category overall, as pulmonology practices convert equipment specifications to cut hospital readmissions and satisfy remote patient monitoring reimbursement requirements simultaneously. North America holds the largest regional share on its concentrated respiratory disease treatment spend and device innovation base, while India's expanding respiratory disease burden and healthcare infrastructure investment is now the single fastest-growing national market this report tracks closely.
Forty-two percent concentration among the top five manufacturers, evaluated here on estimated global installed base, reflects a meaningfully consolidated equipment category where connectivity engineering and predictive software depth increasingly separate leaders from the long tail of regional device makers. Remote monitoring integration and exacerbation prediction algorithms increasingly determine which suppliers can win multi-year health system contracts from those still bidding purely on unit price.
Market Definition
The pulmonology devices market comprises diagnostic, therapeutic, and monitoring equipment used to assess and treat respiratory conditions, including spirometers, ventilators, CPAP and BiPAP systems, bronchoscopes, nebulizers, and connected respiratory monitors sold to hospitals, clinics, and home care settings. It excludes general anesthesia machines not configured for pulmonary function assessment, surgical instruments unrelated to airway visualization, and consumer-grade wellness wearables lacking formal clinical respiratory monitoring validation.
Base Year Value
$9.5B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
7.6% base case. Bull 8.9%. Bear 6.3%.
Fastest Growth Segment
Connected and AI-Enabled Respiratory Monitoring Devices: 11.4% CAGR
Fastest Growth Country
India: 10.8% CAGR
Fastest Growth Region
South Asia and Pacific: 9.6% CAGR
Largest Region
North America: 29% of 2025 global value
Market Leaders
Medtronic plc, ResMed Inc., Koninklijke Philips N.V., GE HealthCare Technologies Inc., and Drägerwerk AG & Co. KGaA lead the category. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Pulmonology Devices Market Forecast Scenarios

pulmonology-devices-market-size-forecast-scenario-1787309019785
Between 2020 and 2025 the category grew at roughly 6.6 percent annually as hospitals and clinics steadily expanded ventilation and diagnostic capacity following pandemic-era respiratory care investment across major healthcare regions. Connected monitoring systems remained a minority of unit volume through most of that stretch. Standalone diagnostic instruments still dominated routine outpatient assessment broadly. Manufacturing capacity additions lagged demand across the period.
The base case assumes 7.6 percent annual growth through 2036, anchored in three mechanisms: continued global respiratory disease burden sustaining baseline diagnostic and therapeutic device demand across all formats combined, accelerating conversion from standalone instruments toward connected and AI-enabled monitoring among health systems facing readmission-reduction reimbursement requirements, and expanding respiratory disease treatment capacity across South Asia driving new device demand well ahead of the category average. Connectivity requirements keep consolidating volume among fewer, qualified manufacturers.
A bull case builds around health systems accelerating connected monitoring adoption faster than expected to address readmission-reduction mandates, pushing growth toward 8.9 percent. The bear case centers on reimbursement policy uncertainty slowing capital investment in new connected devices, pulling growth down toward 6.3 percent if health systems delay upgrading from standalone instruments. Component sourcing costs will likely shape that timeline.

Where Standalone Diagnostics Meet Connected Monitoring

Pulmonology devices occupy an unusual position within respiratory care, where a genuinely mature diagnostic and therapeutic category now competes directly against connected, software-managed monitoring systems for the same clinical specification line item. That shift means growth increasingly concentrates in whichever format a given health system's readmission-reduction requirement actually demands. Established clinical service relationships remain the strongest defense smaller device makers sti
MARKET CONCENTRATION (CR5)42%Installed base concentrated among leading global device makers
AVERAGE SELLING PRICE$14,500 per unitBlended price across diagnostic and connected monitoring formats
TOP PRODUCING COUNTRY SHAREUnited States, 26% of installed baseReflects concentrated respiratory device innovation and manufacturing capacity
CAPACITY UTILISATION73%Precision assembly lines run below full nameplate capacity
COMPONENT COST SHARE41% of production costSensors and connectivity electronics dominate unit cost structure
CONNECTED FORMAT PENETRATION23% of unit volumeShare of devices now sold with integrated remote connectivity
Competitive character centers on remote monitoring reliability and predictive analytics accuracy rather than pure unit price alone, since large health systems increasingly specify device format based on total readmission-reduction value rather than capital cost in isolation. Connectivity engineering depth increasingly determines which manufacturers can even bid on large-scale health system contracts. Suppliers lacking documented predictive software integration increasingly struggle to even qualify for large multi-year supply agreements.
Over the next decade, connected monitoring adoption and predictive software depth will likely determine how much of the category's remaining growth potential converts into actual volume rather than continuing to split share between standalone and connected formats indefinitely. Smaller outpatient clinics, where standalone diagnostic instruments still satisfy assessment requirements, represent legacy formats' most defensible remaining stronghold industry-wide.
"A spirometer used to be judged purely on measurement accuracy. Now a health system wants it to flag an exacerbation three days before a patient shows up in the emergency room, and that single requirement has rewritten who gets invited to bid."
Director, Respiratory Diagnostic and Therapeutic Devices Practice · MMA Respirat

Market Trends

Connected Monitors Displace Standalone Instruments in Chronic Care Management

Health systems increasingly specify connected respiratory monitoring devices over conventional standalone instruments for their flagship chronic obstructive pulmonary disease management programs, converting equipment specifications well ahead of any regulatory mandate requiring the switch specifically. Readmission-reduction reimbursement requirements at major health systems increasingly extend into equipment choices, giving procurement teams formal internal justification for paying a meaningful capital premium that previous cost-only purchasing criteria would have rejected outright. Manufacturers with established connectivity capability report order volume from chronic care management accounts growing meaningfully faster than standalone instrument sales, reflecting a genuine shift rather than simple marketing repositioning.
Market Impact: Adds 5% annual baseline treatment d

AI-Driven Exacerbation Prediction Reshapes Equipment Procurement Decisions

Health systems increasingly require AI-driven exacerbation prediction software bundled with monitoring hardware before a system can even enter their approved capital equipment list, pushing manufacturers to secure software development capability well ahead of broader industry adoption of similar requirements across the category. Software vendors and device makers increasingly coordinate integration testing directly, since a maker unable to demonstrate reliable prediction accuracy risks losing approved-supplier status with major health system accounts entirely. This dynamic is consolidating demand around makers with dedicated software capability, favoring larger manufacturers over smaller regional suppliers offering only standalone commodity formats.
Market Impact: Adds 7% annual treatment-driven dem

Market Opportunities and Growth Drivers

Global Respiratory Disease Burden Sustains Baseline Demand

Global respiratory disease prevalence continues expanding steadily across both developed and emerging healthcare markets, and a meaningful share of that burden still requires pulmonology device support regardless of which specific format a given health system ultimately selects for its respiratory care pathway. Health systems report that dedicated pulmonology devices remain the preferred format specifically for chronic conditions that general monitoring equipment handles less effectively than devices built for repeated respiratory-specific assessment. This baseline demand floor supports steady volume even as format choice continues shifting within the category. Certification depth increasingly separates preferred suppliers from the rest.
Market Impact: Delays roughly 14% of planned upgra

Respiratory Disease Treatment Capacity Expands Across South Asia

Respiratory disease treatment capacity continues expanding meaningfully across India and other South Asian markets, driven by both domestic disease burden growth and multinational healthcare providers building regional treatment capacity to serve rapidly growing patient populations more efficiently. Health systems report that equipment specification decisions for new respiratory care facilities increasingly default toward connected monitoring from the outset rather than standalone instruments, an advantage that favors manufacturers with established regional service networks over new entrants lacking comparable local support. This treatment-driven volume growth substantially exceeds the modest growth rates typical of mature developed healthcare markets elsewhere.
Market Impact: Adds roughly 29% cost premium curre

Market Restraints and Challenges

Component Cost Volatility Delays Connectivity Investment

Sensor and connectivity electronics component prices both fluctuate meaningfully with broader semiconductor and precision imaging commodity cycles, and health systems facing uncertain capital budgets frequently delay upgrading from standalone instruments to connected devices until pricing stabilizes enough to justify the outlay confidently. The root cause is that connected device conversion requires meaningful upfront capital that smaller health systems cannot easily absorb during volatile component cost periods without straining constrained hospital budgets considerably. Manufacturers are responding by offering phased leasing and value-based reimbursement programs rather than requiring full upfront capital commitment in a single purchase cycle.
Market Impact: Adds 11.4% annual connected segment

Connected System Cost Premium Slows Broader Conversion

Connected respiratory monitoring devices still cost meaningfully more per unit than conventional standalone instruments, a price gap that continues narrowing but has not yet closed enough to make conversion economically self-justifying without a specific readmission-reduction requirement driving the switch. The root cause is that connectivity engineering and predictive software integration remain a smaller manufacturing base than standalone equipment production built up over decades, keeping connected costs elevated until production scale catches up with growing demand. Manufacturers are responding by investing in expanded connectivity component assembly capacity to close that cost gap faster than organic demand would achieve.
Market Impact: Affects procurement for 27% of volu
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the pulmonology devices market by product type, distinguishing diagnostic spirometry, mechanical ventilators, CPAP and BiPAP therapy devices, bronchoscopes and airway visualization devices, nebulizers, and connected AI-enabled monitoring devices because each carries distinct engineering and health system qualification requirements across acute and chronic care settings alike. used across both acute hospital settings and small independent outpatient clinics alike.
pulmonology-devices-market-market-share-analysis-1787309020318

Connected and AI-Enabled Respiratory Monitoring Devices

Connected and AI-enabled respiratory monitoring devices are growing fastest as health systems with formal readmission-reduction requirements convert away from conventional standalone instruments toward devices offering remote patient tracking and predictive exacerbation alerts simultaneously. Manufacturers with established connectivity capability and predictive software capture disproportionate share, since that capability requires considerable investment that smaller regional device makers generally cannot justify without confidence in sustained demand growth from major health system accounts. Readmission-reduction reimbursement requirements at major health systems increasingly extend into equipment specifications, giving procurement teams formal internal justification for paying a meaningful capital premium that previous cost-only purchasing criteria would have rejected outright. This segment commands meaningfully higher per-unit pricing than commodity standalone systems given its specialized connectivity and software investment.
CAGR 11.4%

Bronchoscopes and Airway Visualization Devices

Bronchoscopes and airway visualization devices form the second-fastest-growing segment, offering AI-assisted navigation and single-use disposable configurations that appeal to health systems seeking both reduced infection risk and improved diagnostic accuracy during airway procedures compared to reusable reprocessed instruments. Manufacturers increasingly develop single-use formats optimized for consistent image quality and rapid procedural deployment, deepening technical relationships with health systems that favor established suppliers over new entrants lacking comparable imaging validation investment and documentation. This segment benefits from genuine differentiation within the broader device category itself, since disposable bronchoscopy formats target infection-control-focused procedures specifically rather than the reusable positioning that conventional bronchoscopes increasingly occupy. Certification investment here remains meaningful but distinct from the connected segment's approach.
CAGR 8.8%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America holds the largest share on its concentrated respiratory disease treatment spend and device innovation base, while Western Europe follows on established healthcare infrastructure. South Asia and Pacific is growing fastest as respiratory disease treatment capacity expands. Overall demand keeps tracking global healthcare investment growth closely.

North America

United States health systems anchor North American demand, with connected respiratory monitoring adoption accelerating meaningfully across major hospital networks given the region's concentrated readmission-reduction reimbursement framework. Canada's smaller market follows broadly similar consumption patterns, benefiting from close clinical collaboration integration with United States health systems given cross-border medical device regulatory alignment. Readmission-reduction-driven connected adoption has accelerated meaningfully among large health systems with formal value-based care commitments, though standalone instruments still dominate smaller outpatient clinics across most of the region. Growth here trails East Asia and South Asia because the region's respiratory device installed base is comparatively mature and already largely built out. Certification costs remain a genuine barrier for smaller regional device makers and clinics.
Share: 29% | CAGR: 8.4% (2026 to 2036)

Western Europe

Germany, the United Kingdom, and France lead Western European demand through well-developed respiratory care infrastructure and some of the world's most established national health service networks, pushing connected monitoring adoption faster here than in most other regions globally. European Union medical device regulation increasingly favors validated connected monitoring formats over conventional standalone alternatives, adding regulatory tailwind that supports category conversion across most member states specifically. The region has also seen a fast standalone-to-connected substitution rate, reflecting its advanced national health service funding environment and sophisticated clinical base. Growth trails the global average because the region combines both meaningful format substitution pressure and a mature, thoroughly penetrated respiratory device installed base.
Share: 24% | CAGR: 6.3% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
pulmonology-devices-market-country-cagr-analysis-1787309020831

Where Device Makers Can Defend Margin and Grow

Margin defense in pulmonology devices depends heavily on expanding connectivity engineering capacity, securing predictive software integration depth, and locking health system contracts around exacerbation prediction reliability that thin commodity margins cannot easily replicate on their own without meaningful investment. The four levers below target distinct points fragmented regional device makers cannot easily replicate on their own.

Connectivity Engineering and Capacity Expansion Program

Readmission-reduction-driven demand for connected respiratory monitoring devices continues outpacing industry-wide connectivity engineering capacity additions, creating a genuine premium pricing opportunity for manufacturers investing directly in expanded connectivity and predictive software engineering ahead of broader industry adoption across the category and its major health system customer base. Manufacturers building dedicated connectivity capacity now capture premium pricing from readmission-conscious health system customers before capacity constraints ease and competitive pressure intensifies across the segment considerably. Early capacity investors report capturing roughly 26 percent more connected volume share than competitors still dependent on constrained third-party connectivity capacity.
Market Impact: Captures roughly 26% more connected

AI Prediction Software Integration and Partnership Program

Health systems increasingly require AI-driven exacerbation prediction software bundled with monitoring hardware, and manufacturers investing directly in long-term software development partnerships capture approved-supplier status that translates into meaningful order volume from the largest, most value-based-care-focused health system accounts. Manufacturers with secured software partnerships report winning roughly 23 percent more large health system contract bids than competitors lacking comparable integration agreements and software validation documentation. Building this software portfolio requires sustained development investment, but it captures customers with meaningfully higher switching costs once care pathways are calibrated to a specific software platform. That reliability increasingly separates preferred suppliers from the rest.
Market Impact: Wins roughly 23% more large health

Multi-Year Fixed-Price Component and Sensor Contracts

Sensor and connectivity electronics component costs fluctuate meaningfully with broader semiconductor and precision imaging commodity market cycles, and manufacturers without long-term supply agreements absorb that volatility directly into thin margins during tight-supply periods that recur unpredictably across both component categories entirely. Manufacturers negotiating multi-year fixed-price contracts protect margin predictability even during industry-wide price spikes exceeding 20 percent, a stability smaller regional competitors without comparable purchasing scale genuinely cannot replicate independently across their own supply relationships. This approach also improves supply reliability during tight-capacity periods. Manufacturers without such agreements face repeated renegotiation cycles that erode pricing discipline over time.
Market Impact: Protects margin during roughly 15 t

Value-Based Leasing Program for Smaller Health Systems

Capital budget constraints represent a genuine adoption barrier that keeps smaller health systems on standalone instruments longer than their readmission-reduction requirements would otherwise justify, and manufacturers developing value-based leasing programs that reduce upfront capital outlay can capture accounts previously lost to budget approval delays specifically. Companies successfully demonstrating flexible leasing terms capture referral volume from smaller health systems that competing formats have not yet fully addressed, a genuinely underserved segment current outright-purchase models cannot efficiently serve. Early leasing adopters report expanding addressable smaller-health-system accounts by roughly 18 percent. This pocket grows steadily over time.
Market Impact: Expands smaller-health-system accou

Who Controls the Margin Pool

Five manufacturers, evaluated here on estimated global installed base, hold roughly forty-two percent of the pulmonology devices category between them, a meaningfully consolidated structure reflecting how strongly connectivity engineering depth favor established device makers over regional competitors. The gap between the largest producers and the long tail of regional device makers is meaningful on pure engineering capability, and predictive software and sensor depth increasingly widen that gap
Current competitive activity centers on three fronts: connectivity engineering capacity expansion to capture readmission-reduction-driven demand, AI prediction software partnerships to defend health system contracts, and value-based leasing program development to capture budget-constrained smaller accounts. Larger manufacturers are also acquiring smaller regional device makers to expand geographic coverage without building new connectivity capacity from scratch entirely. Consolidation among smaller regional device makers is also accelerating as software costs rise.

Pressure is building from connectivity and AI-enabled specialists steadily expanding share across readmission-focused health system accounts, a threat concentrated specifically in the highest-value product tiers where predictive accuracy matters more than pure unit price. Ranking shifts are most likely among smaller regional device makers unable to fund software investment, several of which MMA expects to exit or consolidate within the next few years.
pulmonology-devices-market-company-positioning-matrix-1787309021352

Competitive Moat and Risk Dimensions

MEDTRONIC PLC

Moat: Deep Ventilation Engineering Base

Medtronic maintains genuine depth in mechanical ventilation engineering developed across decades of critical care instrumentation experience, giving it meaningfully broader clinical validation expertise and global service network coverage than competitors who entered the category more recently. Customers value that heritage when evaluating long-term equipment reliability.
MEDTRONIC PLC

Risk: Premium Pricing Limits Smaller Accounts

Medtronic's premium ventilation positioning and engineering depth carry meaningfully higher pricing than commodity standalone alternatives, leaving it less competitive among smaller outpatient clinics and budget-constrained accounts that prioritize cost over documented clinical performance. That exposure grows more pronounced as smaller accounts seek lower-cost alternatives instead.
RESMED INC.

Moat: Deep Connected Respiratory Base

ResMed maintains genuine depth in connected CPAP and remote patient monitoring software developed specifically for chronic respiratory care workflows, giving it meaningfully better ability to serve health systems seeking documented readmission-reduction performance than competitors relying on less established connected platforms. That depth shortens qualification cycles competitors cannot easily match.
RESMED INC.

Risk: Narrower Acute Care Portfolio

ResMed's mechanical ventilation and acute care instrument portfolio remains comparatively less developed than diversified competitors who built broader critical care capability earlier, leaving it somewhat exposed among health systems seeking a single supplier spanning both chronic and acute respiratory care. Closing that gap will require sustained investment over time.

Players Tracked

Prominent Players

Medtronic plc
ResMed Inc.
Koninklijke Philips N.V.
GE HealthCare Technologies Inc.
Drägerwerk AG & Co. KGaA

Other Key Players

Becton, Dickinson and Company
Vyaire Medical, Inc.
Smiths Medical
Fisher & Paykel Healthcare Corporation Limited
Teleflex Incorporated
Hamilton Medical AG
Nihon Kohden Corporation
Invacare Corporation
Inogen, Inc.
Vapotherm, Inc.
Cosmed S.r.l.
MGC Diagnostics Corporation
Olympus Corporation
KARL STORZ SE & Co. KG
Ambu A/S

Recent Developments

MARCH 2025

Medtronic Expands Connectivity Engineering Capacity in Minnesota

Medtronic completed an organic capacity expansion at its existing Minnesota facility, adding dedicated connectivity and predictive software engineering capability to meet growing demand from health systems converting away from standalone instruments. Timeline details for the expansion remain forthcoming for now. Both facilities will support ongoing customer trials.
Signal: Reflects manufacturers investing directly
JUNE 2025

ResMed Signs Multi-Year Software Integration Partnership Agreement

ResMed signed a multi-year software development partnership agreement with an AI-driven exacerbation prediction vendor to accelerate integration across its connected monitoring product line, becoming a preferred supplier recommended directly to health systems with formal value-based care requirements. The agreement includes joint development of future software modules as well.
Signal: Shows manufacturers pursuing direct softwa
SEPTEMBER 2025

Philips Acquires Regional Device Maker in Southeast Asia

Philips acquired a majority equity stake in a regional Southeast Asian respiratory device maker, expanding its manufacturing footprint to serve the region's growing respiratory disease treatment sector, which has become one of the fastest-growing demand pools within the broader category. Terms of the transaction were not disclosed publicly.
Signal: Signals established manufacturers acquirin

Sensor and Connectivity Electronics Component Exposure

Sensors and connectivity electronics together represent an estimated 38 to 46 percent of cost of goods sold for a typical pulmonology device, sourced from global precision electronics and semiconductor production concentrated among a relatively small number of major component suppliers. This dual dependency leaves manufacturers with limited substitution options when either component category faces disruption simultaneously.
Precision sensor component prices rose meaningfully during 2024 after global semiconductor supply tightened following capacity constraints across several major producing regions, according to figures the EIA tracks for comparable electronics-intensive manufacturing input costs alongside broader industrial commodity conditions across domestic and internationally traded volumes. Smaller manufacturers without long-term component contracts reported input cost increases exceeding 19 percent within two quarters, a shock larger integrated manufacturers with hedged supply absorbed more comfortably.

Smaller regional device makers without the purchasing scale to negotiate multi-year fixed-price component contracts absorb raw material volatility directly into thin margins, while the largest manufacturers use long-term supply agreements spanning both component categories simultaneously. This gap compounds over time: undercapitalized device makers either raise prices, risking volume loss to established competitors, or hold pricing and erode margin, a choice larger integrated manufacturers rarely face.
pulmonology-devices-market-cost-volatility-analysis-1787309021547

Multi-Year Fixed-Price Component Supply Contracts

Locking sensor and connectivity electronics component procurement into two to four year fixed-price agreements with primary suppliers protects margin predictability during spot market volatility, though it requires accepting somewhat higher baseline pricing during calm periods, a trade-off larger manufacturers with stronger balance sheets absorb more comfortably than smaller regional device makers operating on thinner working capital margins.

Vertical Integration into Precision Sensor Assembly

The largest manufacturers are selectively integrating backward into sensor and connectivity electronics assembly, reducing dependence on open-market purchasing even though the capital investment required puts this option genuinely out of reach for smaller regional device makers competing primarily on price and delivery proximity to their health system customers. This approach also improves supply reliability during tight-capacity periods.

Regional Component Sourcing Diversification Strategy

Shifting a portion of component procurement toward Southeast Asian and Eastern European producing regions reduces exposure to any single producing region's supply disruption or currency risk simultaneously, though this diversification requires meaningful supplier qualification investment that smaller manufacturers often cannot justify. Early movers report meaningfully steadier input pricing overall. Fewer manufacturers have made this shift industry-wide so far.

Portfolio Architecture for Margin Defence

Pulmonology device portfolios split cleanly into three margin tiers. Volume commodity-adjacent standalone diagnostic instruments sold through competitive bidding to smaller clinics carry the thinnest margins but the highest unit volume, competing primarily on price and availability rather than connectivity credentials. Premium connected and AI-enabled formats command meaningfully higher margins tied to connectivity depth and software capability rather than mechanical cost alone.
The tension between commodity standalone volume and premium connected positioning shapes nearly every strategic decision manufacturers make, from where to invest connectivity capital, to which health system relationships to prioritize for joint software development. Chasing volume through commodity standalone formats generates steady cash flow but exposes manufacturers directly to substitution pressure from connected alternatives, while over-indexing on premium connected positioning limits addressable market size given how much smaller the truly readmission-driven health system base remains today. Manufacturers unable to fund software investment risk sliding entirely into the lowest-margin commodity tier.

High-value margin pools concentrate specifically in connected monitoring and disposable bronchoscopy formats, both growing faster than the broader category and commanding pricing that neither commodity standalone diagnostics nor standard nebulizers currently achieve at comparable scale within the category.

Volume / Commodity-Adjacent Tier

Standard standalone spirometers and nebulizers sold through competitive bidding to smaller clinics, competing primarily on price, availability, and basic clinical functionality rather than connectivity credentials, supported by lower barriers to entry across many regional device makers.
Gross Margin: 19-25%

Premium / Certified Tier

Connected and AI-enabled monitoring formats backed by formal predictive software validation and clinical testing, sold primarily to readmission-focused health systems requiring documented performance credentials. This tier increasingly determines which manufacturers win large multi-year health system contracts.
Gross Margin: 34-42%

Sustainability / Regulatory / Next-Generation Tier

Next-generation predictive analytics platforms and remote patient management software systems targeting value-based-care-focused health systems ahead of anticipated reimbursement policy tightening across major markets. Margins here remain the highest in the category but require sustained software and validation investment to defend.
Gross Margin
pulmonology-devices-market-portfolio-architecture-1787309022036

High-value Sub-segments and Strategic Watch-out

Connected and AI-Enabled Formats

Connected respiratory monitoring devices represent the fastest-growing, highest-margin pocket of the category, moving from niche specialty product into standard readmission-driven procurement requirement as health system value-based-care commitments continue expanding across major accounts. Suppliers without dedicated connectivity capability risk losing these accounts entirely. That risk compounds annually as connectivity standards rise.

AI Exacerbation Prediction Software

Software formally qualified for AI-driven exacerbation prediction is growing steadily as health systems increasingly specify automated risk-scoring capability, commanding a meaningful price premium that reflects the development investment required to earn approved-supplier status. Suppliers lacking software depth increasingly struggle to even qualify for these bids.

Standard Standalone Diagnostic Devices

The largest volume segment by unit count, standard standalone spirometers and diagnostic instruments sold through established distributor relationships anchor category revenue even as growth moderates, remaining the primary entry point through which most smaller clinics first specify respiratory assessment. Pricing pressure remains intense among competing regional device makers.

Connected Format Substitution Threat

Connected and AI-enabled specialists capturing share among readmission-focused health system accounts represent a genuine strategic threat to legacy standalone device makers lacking comparable connectivity and software capability, eroding volume among the largest, most value-based-care-focused accounts. Manufacturers that close this gap fastest stand to defend the most volume.

Where Software Depth Decides Recurring Revenue

Pulmonology device demand tracks respiratory disease treatment investment directly rather than generating true durable-goods-style replacement demand on a fixed cycle, since equipment is replaced through ongoing capital procurement tied to clinical program expansion rather than any fixed lifespan consideration. Repeat purchase comes from ongoing health system and manufacturer relationships rather than any individual unit's usage pattern, meaning manufacturer revenue depends heavily on retaining
Adoption depth varies considerably by end-use vertical. Chronic disease management programs show the most volatile format loyalty, since readmission-reduction requirements and value-based-care audits can shift an entire clinical pathway's specification relatively quickly once connected alternatives prove commercially viable. Routine outpatient clinics show meaningfully deeper standalone loyalty, since basic diagnostic accuracy and lower patient acuity favor durable simple formats over more expensive connected alternatives. Mid-tier specialty pulmonology practices sit in a defensible middle position.

A generational shift among health system procurement buyers, increasingly trained to weigh total readmission-reduction and predictive value rather than upfront capital price alone, is reshaping specification decisions gradually, favoring connected and software-integrated formats over undifferentiated commodity standalone systems even where switching costs remain meaningfully higher today across most clinical programs.
pulmonology-devices-market-end-use-penetration-index-1787309022525

Where Device Makers Should Focus Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / CONNECTIVITY CAPACITY INVESTMENT

Expand engineering capacity to capture readmission demand growth

Readmission-reduction-driven demand for connected respiratory monitoring devices continues outpacing industry-wide connectivity engineering capacity additions, creating a genuine premium pricing opportunity for manufacturers investing directly in expanded connectivity and predictive software engineering ahead of broader industry adoption across the category and its major health system customer base today. Manufacturers building dedicated connectivity capacity now capture premium pricing from readmission-conscious health system customers before capacity constraints ease and competitive pressure intensifies across the segment considerably. Companies that delay this investment risk losing readmission-driven accounts permanently to competitors offering more reliable connectivity supply.
02 / SOFTWARE INTEGRATION PARTNERSHIPS

Build AI prediction capability to defend health system contracts

Health systems increasingly require AI-driven exacerbation prediction software bundled with monitoring hardware, and manufacturers investing directly in long-term software development partnerships capture approved-supplier status that translates into meaningful order volume from the largest, most value-based-care-focused health system accounts available today. Building this software portfolio requires sustained development investment, but it captures customers with meaningfully higher switching costs once care pathways are calibrated to a specific software platform and documented validation history. Waiting risks permanently ceding these valuable accounts to competitors with faster software timelines instead.
03 / COMPONENT SUPPLY HEDGING

Lock multi-year contracts to protect margin against volatility

Sensor and connectivity electronics component costs fluctuate meaningfully with broader semiconductor and precision imaging commodity cycles, and manufacturers without long-term supply agreements absorb spot-market volatility directly into thin margins during tight-supply periods that recur unpredictably across both component categories without warning. Manufacturers negotiating multi-year fixed-price contracts protect margin predictability even during industry-wide price spikes, a stability smaller regional competitors without comparable purchasing scale cannot replicate on their own without meaningful investment. Manufacturers that skip this hedging discipline remain exposed every time either component market tightens unexpectedly.
04 / VALUE-BASED LEASING PROGRAMS

Build flexible financing to capture budget-constrained accounts

Capital budget constraints represent a genuine adoption barrier that keeps smaller health systems on standalone instruments longer than their readmission-reduction requirements would otherwise justify, and manufacturers developing value-based leasing programs that reduce upfront capital outlay can capture accounts previously lost to budget approval delays specifically and permanently. Companies successfully demonstrating flexible leasing terms capture referral volume from smaller health systems that competing formats have not yet fully addressed, an underserved segment current outright-purchase models cannot serve. This investment compounds as smaller health systems increasingly weigh financing flexibility alongside unit cost.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Pulmonology Devices Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Pulmonology Devices Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a regional health system generating approximately 890 million dollars in annual revenue (client-reported, unverified by MMA), operating four hospitals and a network of outpatient pulmonology clinics. The company had relied on conventional standalone diagnostic instruments across its chronic disease management program and faced rising readmission rates among its highest-risk chronic obstructive pulmonary disease patient population.
STRATEGIC CHALLENGE
Management needed to determine whether deploying connected respiratory monitoring devices across the chronic disease program justified the capital cost and clinical workflow changes required, while also evaluating whether a partial deployment targeting only the highest-risk patient cohort could deliver most of the readmission-reduction benefit at a fraction of the cost. That decision carried real budget implications heading into the next capital planning cycle.
MMA APPROACH
MMA conducted primary interviews with the client's clinical operations, quality assurance, and value-based care contracting teams, benchmarked connected monitoring deployment outcomes at comparable regional health systems, and modeled cost and readmission-rate impact under three deployment scenarios before presenting a phased recommendation. MMA also reviewed the client's current device relationships to assess deployment feasibility.
KEY FINDINGS
  1. The client's highest-risk chronic obstructive pulmonary disease patient cohort accounted for the large majority of preventable readmissions over the preceding two years, per internal quality records reviewed.
  2. Comparable health systems that deployed connected monitoring for high-risk cohorts reported measurably reduced thirty-day readmission rates within two quarters, according to comparable case data MMA reviewed.
  3. Partial deployment targeting only the highest-risk patient cohort would cost meaningfully less upfront than full program-wide deployment based on comparable capital estimates reviewed.
  4. Connected monitoring device costs ran an estimated 28 percent above conventional standalone instruments across the specific formats evaluated for the client's chronic disease program volume.
CLIENT PROFILE
The client is a regional health system generating approximately 890 million dollars in annual revenue (client-reported, unverified by MMA), operating four hospitals and a network of outpatient pulmonology clinics. The company had relied on conventional standalone diagnostic instruments across its chronic disease management program and faced rising readmission rates among its highest-risk chronic obstructive pulmonary disease patient population.
STRATEGIC CHALLENGE
Management needed to determine whether deploying connected respiratory monitoring devices across the chronic disease program justified the capital cost and clinical workflow changes required, while also evaluating whether a partial deployment targeting only the highest-risk patient cohort could deliver most of the readmission-reduction benefit at a fraction of the cost. That decision carried real budget implications heading into the next capital planning cycle.
MMA APPROACH
MMA conducted primary interviews with the client's clinical operations, quality assurance, and value-based care contracting teams, benchmarked connected monitoring deployment outcomes at comparable regional health systems, and modeled cost and readmission-rate impact under three deployment scenarios before presenting a phased recommendation. MMA also reviewed the client's current device relationships to assess deployment feasibility.
KEY FINDINGS
  1. The client's highest-risk chronic obstructive pulmonary disease patient cohort accounted for the large majority of preventable readmissions over the preceding two years, per internal quality records reviewed.
  2. Comparable health systems that deployed connected monitoring for high-risk cohorts reported measurably reduced thirty-day readmission rates within two quarters, according to comparable case data MMA reviewed.
  3. Partial deployment targeting only the highest-risk patient cohort would cost meaningfully less upfront than full program-wide deployment based on comparable capital estimates reviewed.
  4. Connected monitoring device costs ran an estimated 28 percent above conventional standalone instruments across the specific formats evaluated for the client's chronic disease program volume.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 4): Deploy connected monitoring devices for the highest-risk chronic obstructive pulmonary disease patient cohort ahead of the next value-based care contract review. Phase 2: Phase 2 (Months 5 to 10): Formalize a long-term software integration agreement with a qualified manufacturer to secure consistent predictive analytics capability. Phase 3: Phase 3 (Months 10 to 16): Evaluate readmission-rate outcomes and expand connected deployment to additional patient cohorts based on demonstrated results.
OUTCOME
Within sixteen months, the client reported a meaningful reduction in thirty-day readmission rates among the deployed patient cohort (client-reported, unverified by MMA), while phased deployment kept capital investment aligned with available budget. Management credited the phased, evidence-driven approach with protecting patient outcomes without overcommitting capital upfront.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Pulmonology Devices Market?

The pulmonology devices market reached an estimated 9.5 billion dollars in 2025. Growth is being driven by connected monitoring conversion and expanding global respiratory disease treatment investment.

How large will the Pulmonology Devices Market be by 2036?

MMA projects the market will reach approximately 21.27 billion dollars by 2036 under the base case scenario, roughly 2.08 times the 2026 starting value over the ten-year forecast window.

What is the CAGR for the Pulmonology Devices Market 2026 to 2036?

The base case CAGR is 7.6 percent annually through 2036, with a bull case of 8.9 percent and a bear case of 6.3 percent depending on connected conversion pace.

Which segment is growing fastest?

Connected and AI-enabled respiratory monitoring devices are growing fastest, at roughly 11.4 percent annually, nearly 1.50 times the category average as health systems convert away from standalone instruments.

Who are the major companies in the Pulmonology Devices Market?

Medtronic, ResMed, Philips, GE HealthCare, and Dräger all currently lead the category based on estimated global installed base across major regions. Concentration remains high given the category's engineering-intensive entry barriers.

Which country is growing fastest?

India is the fastest-growing major market, expanding at an estimated 10.8 percent annually as respiratory disease burden and healthcare infrastructure investment both continue rising steadily nationwide.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Product Type

  • Diagnostic Spirometry Devices
  • Mechanical Ventilators
  • CPAP and BiPAP Therapy Devices
  • Bronchoscopes and Airway Visualization Devices
  • Nebulizers and Inhalation Devices
  • Connected and AI-Enabled Monitoring Devices

By End-Use Industry

  • Hospital and Acute Care
  • Outpatient Pulmonology Clinics
  • Home Care and Chronic Disease Management
  • Ambulatory Surgical Centers

By Commercial Dimension

  • Direct Health System Supply
  • Distributor and Wholesale Sales
  • Value-Based Leasing Programs
  • Export and Import Volume

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The pulmonology devices market comprises diagnostic, therapeutic, and monitoring equipment used to assess and treat respiratory conditions, including spirometers, ventilators, CPAP and BiPAP systems, bronchoscopes, nebulizers, and connected respiratory monitors sold to hospitals, clinics, and home care settings. It excludes general anesthesia machines not configured for pulmonary function assessment, surgical instruments unrelated to airway visualization, and consumer-grade wellness wearables lacking formal clinical respiratory monitoring validation.
Quantitative Units
USD billions (current prices); installed base in units where applicable
Segmentation Dimensions
Product Type; End-Use Industry; Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Germany, UK, France, Japan, South Korea, China, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Czech Republic, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Medtronic plc, ResMed Inc., Koninklijke Philips N.V., GE HealthCare Technologies Inc., Drägerwerk AG & Co. KGaA, Becton, Dickinson and Company, Vyaire Medical, Inc., Smiths Medical, Fisher & Paykel Healthcare Corporation Limited, Teleflex Incorporated, Hamilton Medical AG, Nihon Kohden Corporation, Invacare Corporation, Inogen, Inc., Vapotherm, Inc., Cosmed S.r.l., MGC Diagnostics Corporation, Olympus Corporation, KARL STORZ SE & Co. KG, Ambu A/S
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-377
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Pulmonology Devices Market Report (2026 to 2036).

This report provides a comprehensive analysis of the global pulmonology devices market, covering market sizing, segmentation, and regional dynamics across the 2026 to 2036 forecast period. It profiles twenty leading manufacturers spanning commodity standalone and certified connected formats, with detailed competitive positioning, moat and risk analysis for the two category leaders, and recent corporate developments across capacity, partnerships, and acquisitions. The report examines revenue-generation levers, sensor input cost exposure, and portfolio margin economics across three product tiers. It draws on primary survey data from 3,800 respondents and 47 expert interviews conducted across six countries in the fourth quarter of 2025.
Ten-year market sizing and growth forecast
Six-segment product type breakdown with CAGR
Seven-region demand and pricing trend analysis
Twenty-company competitive profiling and moat assessment
Sensor input cost and supply exposure review
Revenue lever and portfolio margin economics

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts